Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 874 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Carcinoma Clear all
Completed No phase listed Observational

Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer

NCT00205010
View directory record Official record
Conditions
Cervical Cancer
Interventions
Lymphoscintigraphy
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268
View directory record Official record
Conditions
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promise Women Project

NCT05862844
View directory record Official record
Conditions
Human Papilloma Virus, Cervical Cancer
Interventions
Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )
Behavioral
Lead sponsor
Mark Dignan, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
4
States / cities
Hampton, Virginia • Henrico, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Self-collection Device for Cervical Cancer Screening

NCT05669911
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus
Interventions
Teal Health Self-Collection Device Group
Device
Lead sponsor
Teal Health, Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Portola Valley, California • Aurora, Colorado • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors

NCT02046265
View directory record Official record
Conditions
Cervical Cancer
Interventions
Step Up to Prevention, Step Up to Prevention: knowledge, Step Up to Prevention:belief, Offered HPV vaccine only
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Phase 1 Interventional

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

NCT02285192
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer
Interventions
18F-Fluorodeoxyglucose (18F-FDG), PET/CT imaging, PET/MRI imaging
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

NCT00005965
View directory record Official record
Conditions
Cervical Cancer
Interventions
bryostatin 1, cisplatin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
New York, New York • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT03738228
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
Interventions
Atezolizumab, Brachytherapy, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.

NCT07351110
View directory record Official record
Conditions
Diabetes, Cervical Cancer (Early Detection), Obesity & Overweight
Interventions
patient navigation and self-collection
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
25 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Phase 2 Interventional

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

NCT03614949
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
Interventions
Stereotactic body radiation therapy (SBRT), Atezolizumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Hilliard, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

NCT01652794
View directory record Official record
Conditions
Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
Radiation · Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380
View directory record Official record
Conditions
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions
tucatinib, trastuzumab, fulvestrant
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Physical Activities by Technology Help (PATH)

NCT03212079
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions
Mycoach Smart Text, MyCoach on Amazon Alexa
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Not applicable Interventional Results available

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

NCT00978874
View directory record Official record
Conditions
Cervical Cancer
Interventions
fludeoxyglucose F 18, fluorine F 18 EF5
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting No phase listed Observational

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

NCT00023660
View directory record Official record
Conditions
Cervical Cancer
Interventions
celecoxib, cisplatin, fluorouracil, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 85 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Burlingame, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable

NCT02157168
View directory record Official record
Conditions
Contraception, Sexually Transmitted Infections, Cervical Cancer
Interventions
Community health worker
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
2,267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT05799274
View directory record Official record
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
RAD301 ([68Ga]-RAD301)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Princeton, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Laparoscopic Approach to Cervical Cancer

NCT00614211
View directory record Official record
Conditions
Cervical Cancer
Interventions
Total Abdominal Radical Hysterectomy, Total Laparoscopic or Robotic Radical Hysterectomy
Procedure
Lead sponsor
Queensland Centre for Gynaecological Cancer
Government
Eligibility
18 Years and older · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
6
States / cities
Baltimore, Maryland • Las Vegas, Nevada • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 10:14 AM EDT
Withdrawn Phase 1 Interventional

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

NCT04411134
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cervical Cancer Screening Among Hispanic Women

NCT01525433
View directory record Official record
Conditions
Cervical Cancer
Interventions
DVD, Promotora
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 21, 2026, 10:14 AM EDT